Has Ronald Chen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,000 in general payments to Ronald Chen, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ronald Chen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ronald Chen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ronald Chen, MD

Radiation Oncology · Kansas City, KSNPI 1265510309

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 15.6%. Reporting peaked in 2022 at $9,813 and has fallen 99.7% since, to $26 in 2025. Among radiation oncology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,000in general payments, 2019–2025

Across 45 payments — averaging $688.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Myovant Sciences Inc.$5K
AbbVie$5K
Astellas Pharma Global Development$4K
Siemens Medical Solutions USA, Inc.$3K
Novartis$3K
Bayer$2K
plus $10K from 9 others

$2,374,330in research payments, 2019–2025

Across 43 payments — averaging $55,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$2.3M
Boston Scientific$35K
Astellas Pharma Global Development$4K
Novartis$4K

What the payments were for

Consulting fees$18,19459%
Speaking & faculty fees$6,39421%
Travel & lodging$5,42217%
Food & beverage$9913%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Myovant Sciences Inc.	1	$4,850
AbbVie	8	$4,613
Astellas Pharma Global Development	7	$4,084
Siemens Medical Solutions USA, Inc.	12	$2,809
Novartis	1	$2,538
Bayer	1	$2,160
Janssen Scientific Affairs, LLC	2	$2,150
Reflexion Medical, Inc.	2	$1,624
Johnson & Johnson	1	$1,440
Telix Pharmaceuticals	2	$1,402
Seagen Inc.	2	$1,210
IBA Proton Therapy, Inc.	3	$1,038
Accuray Incorporated	1	$1,000
Genentech, Inc.	1	$57
Regeneron Healthcare Solutions, Inc.	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ORGOVYX$4,850
PADCEV$4,084
Erleada$3,590
Lupron Depot$2,813
Varian Ethos Treatment Planning$2,378
Xofigo$2,160
ILLUCCIX$2,078
REFLEXION MEDICAL RADIOTHERAPY SYSTEM$1,624
CyberKnife System$1,000
Halcyon$959
ARIA Radiation Therapy Management Software$472
Varian Treatment$136

How this compares

$31,000 in reported general payments places this provider in the 95th percentile of 54 radiation oncology providers in Kansas.

See all radiation oncology providers in Kansas →

Medicare billing

Part B allowed, 2024

$97,364

Medicare patients

205

Services billed

1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	23	$359

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Kansas City

Xinglei ShenKansas City$16K
David AkhavanKansas City$9K
Fen WangKansas City$7K
Gregory GanKansas City$5K
Ronny RotondoKansas City$4K
Jay ShiaoKansas City$3K
Parvesh KumarKansas City$3K
Ryan MorseKansas City$939
Christopher LominskaKansas City$466
Ramesh GadamKansas City$266

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →